The emergence of targeted therapies for EGFR mutations and ALK alterations, as well as PD-L1-directed therapies and their subsequent approvals in the adjuvant setting, marked a turning point that continues to redefine the standard of care in operable NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.